EHA Update 2017 New Data on the Benefits of Novartis Ruxolitinib (Jakavi®) in Polycythemia vera and Myelofibrosis

被引：0
|
作者：
不详
机构：
来源：
TRANSFUSION MEDICINE AND HEMOTHERAPY | 2017年 / 44卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：372 / 372
页数：1
相关论文
共 50 条
  • [1] Real-world Data on Jakavi® (Ruxolitinib) from Novartis show improved Quality of Life in Myelofibrosis and confirmed Efficacy in Polycythemia vera
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (06) : 466 - 466
  • [2] EHA 2019 New Study Data on Ruxolitinib used for treating Patients with Polycythemia vera and Myelofibrosis
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 418 - 418
  • [3] TREATMENT WITH RUXOLITINIB IN MYELOFIBROSIS AND POLYCYTHEMIA VERA EXPERIENCE OF A CENTRE
    Moya Arnao, M.
    Perez Lopez, R.
    Martinez Marin, A.
    Fernandez Poveda, E.
    Navarro Almenzar, B.
    Berenguer Piqueras, M.
    Cabanas Perianes, V
    Salido Fierez, E.
    Moreno Belmonte, M. J.
    Cerezo Manchado, J. J.
    Labbadia, F.
    Blanquer Blanquer, M.
    Garcia Hernandez, A. M.
    Martinez Garcia, A. B.
    Melero Amor, A.
    Rosique Cortina, P.
    Ruiz Sanchez, M.
    Moraleda Jimenez, J. M.
    HAEMATOLOGICA, 2017, 102 : 332 - 333
  • [4] ASH 2019-Real World and clinical Data demonstrate the Benefits of Ruxolitinib Therapy from Novartis in Polycythemia Vera (PV)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (03) : 119 - 119
  • [5] Association of ruxolitinib with NMSCs risk in patients with polycythemia vera and myelofibrosis
    Lin, J.
    Li, S.
    Li, S.
    Kiamanesh, E.
    Aasi, S.
    Kwong, B.
    Chang, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S43 - S43
  • [6] Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
    Jeffrey C. Bryan
    Srdan Verstovsek
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1125 - 1142
  • [7] Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
    Bryan, Jeffrey C.
    Verstovsek, Srdan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1125 - 1142
  • [8] Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The "RAMP" Multicenter Prospective Study
    Palandri, Francesca
    Elli, Elena Maria
    Iurlo, Alessandra
    Auteri, Giuseppe
    Trawinska, Malgorzata Monika
    Bonifacio, Massimiliano
    Mendicino, Francesco
    Latagliata, Roberto
    Mazzoni, Camilla
    Biondo, Mattia
    Sangiorgio, Valentina
    Cattaneo, Daniele
    Tamellini, Edoardo
    Abruzzese, Elisabetta
    Krampera, Mauro
    Impera, Stefana
    Garibaldi, Bruno
    Paglia, Simona
    Bartoletti, Daniela
    Vianelli, Nicola
    Cavo, Michele
    Heidel, Florian H.
    Breccia, Massimo
    Caocci, Giovanni
    Palumbo, Giuseppe A.
    BLOOD, 2022, 140 : 9726 - 9728
  • [9] Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
    Dold, Leona
    Lutz, Philipp
    Heine, Annkristin
    Weismuller, Tobias J.
    Strassburg, Christian P.
    Spengler, Ulrich
    CLINICAL CASE REPORTS, 2021, 9 (09):
  • [10] RUXOLITINIB IN VERA POLYCYTHEMIA AND MYELOFIBROSIS: EFFICACY AND SAFETY IN CLINICAL ASSISTANCE PRACTICE
    Ruiz Mercado, M.
    Mata Vazquez, M., I
    Moreno Beltran, M. E.
    Casanova Espinosa, M.
    Rueda Dominguez, A.
    Medina Perez, A.
    HAEMATOLOGICA, 2018, 103 : 355 - 356
12345